enVVeno Medical Corporation reported its financial results for the first quarter of 2026, revealing a net loss of $3.8 million, a 15% decrease from the $4.5 million loss recorded in the same period of 2025. The reduction in net loss was attributed to a $0.9 million decrease in operating expenses, which was partially offset by a $0.2 million decline in other income. The company’s total operating expenses for the quarter were $4.1 million, down from $5.4 million in the prior year, reflecting a strategic shift in focus towards the development of its enVVe System, a non-surgical replacement venous valve.
The company’s cash and cash equivalents stood at $2.6 million as of March 31, 2026, down from $3.1 million at the end of 2025. Total current assets decreased to $25.5 million from $28.8 million, primarily due to a reduction in short-term investments. The company’s total liabilities remained relatively stable at $2.4 million, with current liabilities slightly increasing to $2.1 million from $2.0 million. Stockholders’ equity also saw a decline, dropping to $23.7 million from $27.1 million, largely due to the net loss incurred during the quarter.
In terms of operational developments, enVVeno Medical is advancing its enVVe System, which aims to provide a minimally invasive treatment for severe Chronic Venous Insufficiency (CVI). The company received FDA approval for its Investigational Device Exemption (IDE) application on April 29, 2026, allowing it to commence the pivotal TAVVE study. This study will evaluate the enVVe System in a two-stage process, starting with a cohort of 10 patients, followed by a larger group of 220 patients. The company plans to enroll participants at up to 40 clinical sites across the U.S.
The company’s research and development expenses for the first quarter of 2026 were $2.1 million, a decrease of 17% from $2.6 million in the same quarter of 2025. This decline was primarily due to reduced costs associated with the VenoValve pivotal study, as the company shifts its focus to the enVVe System. Selling, general, and administrative expenses also decreased by 19% to $2.0 million, reflecting lower stock-based compensation costs and other operational efficiencies.
Looking ahead, enVVeno Medical anticipates continued losses as it invests in product development and clinical trials. The company expects its cash burn rate to increase to between $4 million and $5 million per quarter in 2026, but management believes that its current cash and investment balance of approximately $24.9 million will be sufficient to fund operations into the third quarter of 2027. The company is also exploring additional capital-raising opportunities to support its ongoing initiatives and product commercialization efforts.
About enVVeno Medical Corp
enVVeno Medical Corporation is a late-stage medical device company developing bioprosthetic solutions for venous disease, primarily focusing on chronic venous insufficiency. Its flagship products, VenoValve and enVVe, are designed as surgical and non-surgical venous valves to treat severe deep venous conditions. The company aims to improve patient outcomes and reduce healthcare costs through innovative, tissue-based implantable devices targeting a large, underserved market.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.